MediTrack requires all medicines registered with the MoPH to display a two-dimensional barcode on outer packaging following international GS1 standards. Each barcode encodes critical product information including the Global Trade Item Number (GTIN), batch or lot number, and expiry date, enabling precise identification and tracking of every pharmaceutical unit throughout its lifecycle.

The system establishes end-to-end traceability by connecting all pharmaceutical stakeholders including manufacturers, importers, distributors, hospitals, pharmacies, and healthcare entities registered with the MoPH. This integrated approach ensures seamless monitoring of medicine movement from production or importation through storage, distribution, and final dispensing to patients.

For subsidized and high-risk products, particularly cancer drugs, MediTrack implements patient-level tracking requiring dispensing records and patient registration with a Unique Health ID at MoPH-identified centers. This advanced feature prevents diversion to foreign markets and ensures that limited subsidized medicines reach their intended recipients.

MediTrack follows a structured rollout approach that began with a pilot phase in 2018 involving 19 pharmaceutical institutions, expanded to all importers and distributors by 2020, and extended to hospitals and pharmacies by 2022. This methodical implementation ensures smooth adoption across Lebanon's pharmaceutical ecosystem while maintaining regulatory compliance at every stage.